Provided by Tiger Fintech (Singapore) Pte. Ltd.

Adverum Biotechnologies

2.39
-0.0800-3.24%
Volume:38.30K
Turnover:92.08K
Market Cap:49.93M
PE:-0.33
High:2.46
Open:2.45
Low:2.36
Close:2.47
Loading ...

U.S. RESEARCH ROUNDUP-Alphabet, Booking Holdings, Meta

Reuters
·
Yesterday

Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
06 Jun

Adverum Biotechnologies' Chief Development Officer, Seyedkazemi Setareh, Reports Disposal of Common Shares

Reuters
·
17 May

Laurent Fischer, CEO of Adverum Biotechnologies, Reports Disposal of Common Shares

Reuters
·
17 May

Adverum Biotechnologies Is Maintained at Buy by Chardan Capital

Dow Jones
·
15 May

Adverum Biotechnologies Price Target Maintained With a $30.00/Share by HC Wainwright & Co.

Dow Jones
·
15 May

RBC Cuts Price Target on Adverum Biotechnologies to $4 From $5, Keeps Sector Perform, Speculative Risk

MT Newswires Live
·
15 May

Adverum Biotechnologies Q1 EPS $(2.25) Misses $(1.94) Estimate

Benzinga
·
15 May

Adverum Biotechnologies, Inc. Q1 Net Income USD -47.019 Million

THOMSON REUTERS
·
15 May

Adverum Biotechnologies, Inc. Q1 Operating Income USD -48.221 Million

THOMSON REUTERS
·
15 May

Adverum Biotechnologies, Inc. Q1 Basic EPS USD -2.25

THOMSON REUTERS
·
15 May

Adverum Biotechnologies Inc expected to post a loss of $1.81 a share - Earnings Preview

Reuters
·
14 May

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
08 May

Adverum Biotechnologies Inc expected to post a loss of $1.94 a share - Earnings Preview

Reuters
·
05 May

Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
03 May

Truist Removes $40 Price Target on Adverum Biotechnologies, Cites Share Volatility, Keeps Buy Rating

MT Newswires Live
·
21 Apr

Adverum Biotechnologies Is Maintained at Buy by Chardan Capital

Dow Jones
·
17 Apr

RBC Cuts Price Target on Adverum Biotechnologies to $5 From $10, Keeps Sector Perform, Speculative Risk

MT Newswires Live
·
16 Apr

Adverum Biotechnologies Price Target Maintained With a $30.00/Share by HC Wainwright & Co.

Dow Jones
·
16 Apr

RBC Capital Keeps Their Hold Rating on Adverum Biotechnologies (ADVM)

TIPRANKS
·
16 Apr